Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.

Yannick Allanore Madelon C Vonk Oliver DistlerArata AzumaMaureen D MayesMartina GahlemannAlexandra JamesVeronika KohlbrennerMargarida AlvesZsuzsanna H McMahanKristin B Highlandnull null

Published in: Annals of the rheumatic diseases (2022)

The safety profile of nintedanib over 52 weeks of SENSCIS-ON was consistent with that reported in SENSCIS. The change in FVC over 52 weeks of SENSCIS-ON was similar to that observed in the nintedanib group of SENSCIS.

Keyphrases

interstitial lung disease
systemic sclerosis
idiopathic pulmonary fibrosis
rheumatoid arthritis
gestational age
electronic health record
big data
artificial intelligence
replacement therapy
preterm birth